Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1175 USD | -1.26% | +0.34% | +657.96% |
04-19 | Sunshine Biopharma Unit Receives Health Canada Approval for Biosimilar Product | MT |
04-19 | Top Premarket Decliners | MT |
Sales 2024 * | 44.4M 60.56M | Sales 2025 * | 100M 136M | Capitalization | 945K 1.29M |
---|---|---|---|---|---|
Net income 2024 * | - 0 | Net income 2025 * | 12M 16.37M | EV / Sales 2024 * | 0.02 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.01 x |
P/E ratio 2024 * |
1.13
x | P/E ratio 2025 * |
0.08
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.55% |
1 day | -1.26% |
Managers | Title | Age | Since |
---|---|---|---|
Steve Slilaty
CEO | Chief Executive Officer | 71 | 09-10-14 |
Camille Sebaaly
DFI | Director of Finance/CFO | 62 | 09-10-14 |
Marc Beaudoin
COO | Chief Operating Officer | - | 01-24 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Natan
BRD | Director/Board Member | 70 | 22-01-31 |
Steve Slilaty
CEO | Chief Executive Officer | 71 | 09-10-14 |
Camille Sebaaly
DFI | Director of Finance/CFO | 62 | 09-10-14 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- SBFM Stock
- SBFM Stock